Identification of New Predictive Osseointegration Bio-Markers of the Prosthetic Implant in Patients With OsteoArthritis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Osteoarthritis
- Sponsor
- Istituto Ortopedico Rizzoli
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- miRNAs and LncRNA
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The study involves the isolation and cellular, molecular and proteomic characterization of synoviocytes, osteoblasts and chondrocytes from tissue samples obtained from patients undergoing surgery of endo or arthroplasty for osteoarthritis (Experimental Group) or interventions for other causes such as for example periarticular fracture requiring the implantation of a prosthesis (Control Group)
Detailed Description
The study involves the isolation and cellular, molecular and proteomic characterization of synoviocytes, osteoblasts and chondrocytes from tissue samples obtained from patients undergoing surgery of endo or arthroplasty for osteoarthritis (Experimental Group) or interventions for other causes such as for example periarticular fracture requiring the implantation of a prosthesis (Control Group) Deeper analysis of micro Ribo Nucleic Acid (RNA) and Non Coding RNA expressed by the synoviocytes, osteoblasts and chondrocytes will be performed in order to understand their possible involvement in pathways of osteogenic differentiation, through suitable experimental in vitro models of co-cultures. In particular, investigators will focus on the cross-talk between synoviocytes and osteoblasts, cell populations involved in the post-surgical articular microenvironment and on which the osteointegration process of the joint prosthesis depends.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male and Female patients \> 40 years old hospitalized for surgery of endo- or arthroplasty for Osteoarthritis or for surgery for joint traumatic diseases (eg femoral neck fractures) requiring the implantation of a prosthesis
- •Interval of at least three months from any previous infiltrative treatment of any kind;
- •Patients able to provide written informed consent to the study.
Exclusion Criteria
- •Severe cognitive defects or psychiatric disorders;
- •Tumor pathologies or concurrent antineoplastic therapies;
- •Autoimmune diseases (rheumatoid arthritis);
- •Surgery that involves the joint
Outcomes
Primary Outcomes
miRNAs and LncRNA
Time Frame: at the time of surgery (Day0)
expression of miRNAs and LncRNA, from synoviocytes, osteoblasts and chondrocytes detected at the time of surgery
Secondary Outcomes
- Biomarkers useful for predicting the efficiency of osseointegration of the implant(at the time of surgery (Day0))
- Validation of data obtained on miRNAs and lncRNAs(at the time of surgery (Day0))